On Thursday, Madrigal Pharmaceuticals got a positive adjustment to its Relative Strength (RS) Rating, from 90 to 93.
IBD's unique rating measures share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the market's biggest winners tend to have an RS Rating north of 80 as they begin their largest climbs.
Here Are 3 Keys For Successful Stock Investing
Madrigal Pharmaceuticals is not currently showing a potential buy point. See if the stock goes on to form a chart pattern that could kick off a new price move.
Madrigal Pharmaceuticals showed 0% earnings growth in its most recent report. Sales gains came in at 0%.
The company earns the No. 58 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
